title: [Clinical and pharmacoeconomic peculiarities of the treatment with cerebrolysin in the period of rehabilitation of is ischemic stroke.].
abstract: The results of the clinical and pharmacoeconomic study of cerebrolysin in the rehabilitative therapy of ischemic stroke presented in the paper revealed the statistically significant regress of neurological disturbances in patients receiving cerebrolysin in daily dosages of 10 and 20 ml as compared to the control group. The rehabilitation of motor functions was more rapid than sensitive ones in patients receiving cerebrolysin comparing to those switched to the basic antihypertensive and antiaggregate therapy. The positive dynamics of speech rehabilitation was observed, the regress of aphatic disturbances being more significant for daily dosage of 20 ml. Rehabilitation rate in the period of treatment with cerebrolysin was higher for daily dosage of 20 ml than that of 10 ml. A prolonged effect of the drug during the long period after its withdrawal was found that resulted in higher rates of rehabilitation to the 11th week in patients receiving cerebrolysin as compared to the control group. Average total cost of direct medical expenses per a patient estimated in the pharmacoeconomic analysis for the groups receiving cerebrolysin and the control group was higher in the former groups, in particular in that with 20 ml dosage of cerebrolysin. A cost-efficacy analysis revealed that the cost of cerebrolysin treatment per effective unit (a cost of one score on the Lindmark scale and the Barthel scale) was less or comparable in patients receiving cerebrolysin comparing to the control group. The study suggests clinical and pharmacoeconomic expediency of cerebrolysin treatment in rehabilitative period of ischemic stroke.
authors.affiliation: Kafedra nevrologii i neĭrokhirurgii GOU VPO RGMU Roszdrava, Moskva.
authors.forename: E I
authors.initials: EI
authors.lastname: Gusev
authors.forename: A B
authors.initials: AB
authors.lastname: Gekht
authors.forename: Iu B
authors.initials: IuB
authors.lastname: Belousov
authors.forename: N A
authors.initials: NA
authors.lastname: Pavlov
authors.forename: D V
authors.initials: DV
authors.lastname: Galanov
authors.forename: G R
authors.initials: GR
authors.lastname: Popov
authors.forename: L E
authors.initials: LE
authors.lastname: Mil'chakova
mesh_terms: D003362:Cost-Benefit Analysis; D017850:Economics, Pharmaceutical; D006801:Humans; D020521:Stroke / Q000188:drug therapy; D016896:Treatment Outcome